{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:37:00Z","timestamp":1792679820650,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.mehy.2019.02.048","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T02:25:23Z","timestamp":1551320723000},"page":"139-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Is Interleukin-38 a key player cytokine in atherosclerosis immune gene therapy?"],"prefix":"10.1016","volume":"125","author":[{"given":"Abdolreza","family":"Esmaeilzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabnam","family":"Pouyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Erfanmanesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.mehy.2019.02.048_b0005","first-page":"1","article-title":"The enhanced expression of IL-17-secreting T cells during the early progression of atherosclerosis in ApoE-deficient mice fed on a western-type diet","volume":"47","author":"Jeon","year":"2015","journal-title":"J Exp Mol Med"},{"issue":"1","key":"10.1016\/j.mehy.2019.02.048_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5779\/hypothesis.v14i1","article-title":"IL-1R2: a novel approach for gene therapy in atherosclerosis","volume":"14","author":"Ahmadi","year":"2016","journal-title":"Hypothesis"},{"issue":"1","key":"10.1016\/j.mehy.2019.02.048_b0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1083\/jcb.201412052","article-title":"Recent insights into the cellular biology of atherosclerosis","volume":"209","author":"Tabas","year":"2015","journal-title":"J Cell Biol"},{"issue":"6801","key":"10.1016\/j.mehy.2019.02.048_b0020","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/35025203","article-title":"Atherosclerosis","volume":"407","author":"Lusis","year":"2000","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.mehy.2019.02.048_b0025","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2008.10.013","article-title":"The pathology of atherosclerosis: plaque development and plaque responses to medical treatment","volume":"122","author":"Insull","year":"2009","journal-title":"Am J Med"},{"issue":"12","key":"10.1016\/j.mehy.2019.02.048_b0030","first-page":"1946","article-title":"Anti-inflammatory cytokines in subclinical carotid atherosclerosis","volume":"66","author":"Ambrosius","year":"2006","journal-title":"J Neurol Neurol"},{"key":"10.1016\/j.mehy.2019.02.048_b0035","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.diabres.2017.07.013","article-title":"Peripheral leucocytes and tissue gene expression of granzyme B\/perforin system and serpinB9: impact on inflammation and insulin resistance in coronary atherosclerosis","volume":"131","author":"Sanad","year":"2017","journal-title":"Diab Res Clin Pract"},{"issue":"3","key":"10.1016\/j.mehy.2019.02.048_b0040","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000464288","article-title":"Downregulations of CD36 and Calpain-1, inflammation, and atherosclerosis by simvastatin in apolipoprotein E knockout mice","volume":"54","author":"Yin","year":"2017","journal-title":"J Vasc Res"},{"issue":"10","key":"10.1016\/j.mehy.2019.02.048_b0045","first-page":"793","article-title":"IL-35: a potential target for the treatment of atherosclerosis","volume":"68","author":"Huang","year":"2013","journal-title":"Pharmazie"},{"issue":"5","key":"10.1016\/j.mehy.2019.02.048_b0050","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/path.2305","article-title":"Progression of atherosclerosis in ApoE-deficient mice that express distinct molecular forms of TNF-alpha","volume":"214","author":"Canault","year":"2008","journal-title":"J Pathol"},{"key":"10.1016\/j.mehy.2019.02.048_b0055","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijcard.2016.02.142","article-title":"Lack of I\u03baBNS accelerates atherosclerosis in LDL receptor-deficient mice via increased Interleukin-6 production","volume":"211","author":"Akita","year":"2016","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.mehy.2019.02.048_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0171674","article-title":"Rebamipide ameliorates atherosclerosis by controlling lipid metabolism and inflammation","volume":"12","author":"Jhun","year":"2017","journal-title":"PLoS One"},{"issue":"6917","key":"10.1016\/j.mehy.2019.02.048_b0065","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nature01323","article-title":"Atherosclerosis in inflammation","volume":"420","author":"Libby","year":"2002","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.mehy.2019.02.048_b0070","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0021-9150(99)00346-9","article-title":"Chemokines and atherosclerosis","volume":"147","author":"Reape","year":"1999","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.mehy.2019.02.048_b0075","doi-asserted-by":"crossref","first-page":"380","DOI":"10.5114\/ceji.2015.54603","article-title":"Atherosclerosis: a chronic inflammatory disease mediated by mast cells","volume":"40","author":"Conti","year":"2015","journal-title":"Cent Eur J Immunol"},{"issue":"1","key":"10.1016\/j.mehy.2019.02.048_b0080","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1365-2249.2008.03604.x","article-title":"Association of intracellular pro-and anti-inflammatory cytokines in peripheral blood with the clinical or ultrasound indications for carotid endarterectomy in patients with carotid atherosclerosis","volume":"152","author":"Profumo","year":"2008","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.mehy.2019.02.048_b0085","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.atherosclerosis.2015.04.783","article-title":"Novel anti-inflammatory therapies for the treatment of atherosclerosis","volume":"240","author":"Khan","year":"2015","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.mehy.2019.02.048_b0090","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nrcardio.2015.5","article-title":"Anti-inflammatory therapies for atherosclerosis","volume":"12","author":"B\u00e4ck","year":"2015","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"10.1016\/j.mehy.2019.02.048_b0095","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"New Eng J Med"},{"issue":"7","key":"10.1016\/j.mehy.2019.02.048_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0160145","article-title":"Targeting tumor necrosis factor-\u03b1 with adalimumab: effects on endothelial activation and monocyte adhesion","volume":"11","author":"Oberoi","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.mehy.2019.02.048_b0105","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrd3444","article-title":"Anti-inflammatory therapeutics for the treatment of atherosclerosis","volume":"10","author":"Charo","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"22","key":"10.1016\/j.mehy.2019.02.048_b0110","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1111\/bph.13818","article-title":"Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect?","volume":"174","author":"Welsh","year":"2017","journal-title":"Br J Pharmacol"},{"issue":"6","key":"10.1016\/j.mehy.2019.02.048_b0115","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/0129784-200808060-00004","article-title":"Statin adverse effects","volume":"8","author":"Golomb","year":"2008","journal-title":"Am J Cardiovasc Drug"},{"issue":"1","key":"10.1016\/j.mehy.2019.02.048_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.115.002497","article-title":"Overcoming challenges with statin therapy","volume":"5","author":"Spence","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"10.1016\/j.mehy.2019.02.048_b0125","doi-asserted-by":"crossref","first-page":"757","DOI":"10.5551\/jat.35113","article-title":"Anti-inflammatory nanoparticle for prevention of atherosclerotic vascular diseases","volume":"23","author":"Koga","year":"2016","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.mehy.2019.02.048_b0130","first-page":"386","article-title":"IL-38: A new factor in rheumatoid arthritis","volume":"4","author":"Takenaka","year":"2015","journal-title":"Biochem Biophys Rep"},{"issue":"1","key":"10.1016\/j.mehy.2019.02.048_b0135","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/039463201302600103","article-title":"IL-36 receptor antagonist with special emphasis on IL-38","volume":"26","author":"Shaik","year":"2013","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.mehy.2019.02.048_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2018.01462","article-title":"Role of Interleukin-38 in chronic inflammatory diseases: a comprehensive review","volume":"9","author":"Xu","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.mehy.2019.02.048_b0145","first-page":"1","article-title":"The effect of interleukin 38 on angiogenesis in a model of oxygen-induced retinopathy","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci Rep"},{"issue":"14","key":"10.1016\/j.mehy.2019.02.048_b0150","doi-asserted-by":"crossref","first-page":"10308","DOI":"10.1074\/jbc.275.14.10308","article-title":"Identification and initial characterization of four novel members of the interleukin-1 family","volume":"275","author":"Kumar","year":"2000","journal-title":"J Biol Chem"},{"issue":"18","key":"10.1016\/j.mehy.2019.02.048_b0155","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.3748\/wjg.v22.i18.4529","article-title":"Elevated serum interleukin-38 level at baseline predicts virological response in telbivudine-treated patients with chronic hepatitis B","volume":"22","author":"Wang","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.mehy.2019.02.048_b0160","first-page":"1","article-title":"Elevated plasma IL-38 concentrations in patients with acute ST-segment elevation myocardial infarction and their dynamics after reperfusion treatment","volume":"10","author":"Zhong","year":"2015","journal-title":"Mediat Inflamm"},{"issue":"8","key":"10.1016\/j.mehy.2019.02.048_b0165","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1073\/pnas.1121534109","article-title":"IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist","volume":"109","author":"van de Veerdonk","year":"2012","journal-title":"PNAS"},{"issue":"2","key":"10.1016\/j.mehy.2019.02.048_b0170","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/cei.12761","article-title":"Distinct expression of interleukin (IL)-36\u03b1, \u03b2 and \u03b3, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease","volume":"184","author":"Boutet","year":"2016","journal-title":"Clin Exp Immunol"},{"issue":"12","key":"10.1016\/j.mehy.2019.02.048_b0175","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1002\/art.39328","article-title":"Brief report: Interleukin-38 exerts antiinflammatory functions and is associated with disease activity in systemic lupus erythematosus","volume":"67","author":"Rudloff","year":"2015","journal-title":"Arthrit Rheumatol"},{"issue":"7","key":"10.1016\/j.mehy.2019.02.048_b0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0181598","article-title":"Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: possible association with PD-L1 expression","volume":"12","author":"Takada","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.mehy.2019.02.048_b0185","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0092-8674(01)00238-0","article-title":"Atherosclerosis: the road ahead","volume":"104","author":"Glass","year":"2001","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.mehy.2019.02.048_b0190","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.mehy.2014.12.027","article-title":"Autologous Hematopoietic Stem Cells transplantation and genetic modification of CCR5 m303\/m303 mutant patient for HIV\/AIDS","volume":"84","author":"Esmaeilzadeh","year":"2015","journal-title":"Med Hypothesis"},{"issue":"2","key":"10.1016\/j.mehy.2019.02.048_b0195","first-page":"3","article-title":"Novel approaches based on autologous stem cell engineering and gene-modification; evidence for the Cure of HIV\/AIDS","volume":"6","author":"Esmaeilzadeh","year":"2015","journal-title":"J Genet Syndr Gene Ther"},{"issue":"1","key":"10.1016\/j.mehy.2019.02.048_b0200","article-title":"A novel method in gene therapy of HIV","volume":"36","author":"Mirzamohammadi","year":"2007","journal-title":"Iran J Public Health"},{"issue":"1","key":"10.1016\/j.mehy.2019.02.048_b0205","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jmhi.2014.05.002","article-title":"IL-24: a novel gene therapy candidate for immune system upregulation in Hodgkin\u2019s lymphoma","volume":"9","author":"Manesh","year":"2015","journal-title":"J Med Hypotheses Ideas"},{"issue":"1","key":"10.1016\/j.mehy.2019.02.048_b0210","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jmhi.2012.03.007","article-title":"Introducing the immunomodulatory effects of mesenchymal stem cells in an experimental model of Beh\u00e7et\u2019s disease","volume":"6","author":"Mazaheri","year":"2012","journal-title":"J Med Hypotheses Ideas"},{"issue":"2","key":"10.1016\/j.mehy.2019.02.048_b0215","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jmhi.2012.08.003","article-title":"Interleukin-25 as a candidate gene in immunogene therapy of pancreatic cancer","volume":"6","author":"Piri","year":"2012","journal-title":"J Med Hypotheses Ideas"},{"issue":"1","key":"10.1016\/j.mehy.2019.02.048_b0220","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jmhi.2013.06.002","article-title":"Overexpression of MDA-7\/IL-24 as an anticancer cytokine in gene therapy of thyroid carcinoma","volume":"8","author":"Mirzaei","year":"2014","journal-title":"J Med Hypotheses Ideas"},{"key":"10.1016\/j.mehy.2019.02.048_b0225","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.mehy.2017.09.017","article-title":"Interleukin 35 and hepatocyte growth factor; as a novel combined immune gene therapy for multiple Sclerosis disease","volume":"109","author":"Moghadam","year":"2017","journal-title":"Med Hypothesis"},{"issue":"4","key":"10.1016\/j.mehy.2019.02.048_b0230","first-page":"442","article-title":"Adeno-associated virus vector integration","volume":"11","author":"Deyle","year":"2009","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.mehy.2019.02.048_b0235","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/10_005","article-title":"Adeno-associated virus as a gene therapy vector: vector development, production and clinical applications","volume":"99","author":"Grieger","year":"2005","journal-title":"Adv Biochem Eng\/Biotechnol"},{"issue":"5","key":"10.1016\/j.mehy.2019.02.048_b0240","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/ATVBAHA.111.237693","article-title":"Thrombosis, biology v. animal models of atherosclerosis","volume":"32","author":"Getz","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"10.1016\/j.mehy.2019.02.048_b0245","first-page":"631","article-title":"Statin therapy: review of safety and potential side effects","volume":"32","author":"Ramkumar","year":"2016","journal-title":"Acta Cardiol Sin"},{"issue":"15","key":"10.1016\/j.mehy.2019.02.048_b0250","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0169-409X(00)00095-8","article-title":"Gene therapy of chronic inflammatory disease","volume":"44","author":"Hedley","year":"2000","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030698771830820X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030698771830820X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T10:28:57Z","timestamp":1554892137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030698771830820X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":50,"alternative-id":["S030698771830820X"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2019.02.048","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is Interleukin-38 a key player cytokine in atherosclerosis immune gene therapy?","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2019.02.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}